Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Genelux Corp (GNLX)
Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,240
  • Shares Outstanding, K 26,718
  • Annual Sales, $ 11,070 K
  • Annual Income, $ -5,210 K
  • 60-Month Beta -3.07
  • Price/Sales 812.06
  • Price/Cash Flow N/A
  • Price/Book 8.68
Trade GNLX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.21
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +13.59%
on 02/23/24
10.63 -31.61%
on 02/02/24
-3.30 (-31.22%)
since 02/01/24
3-Month
6.40 +13.59%
on 02/23/24
16.60 -56.20%
on 12/28/23
-6.06 (-45.46%)
since 12/01/23
52-Week
6.40 +13.59%
on 02/23/24
40.98 -82.26%
on 06/22/23
-9.63 (-56.98%)
since 03/01/23

Most Recent Stories

More News
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
GNLX : 7.27 (-0.41%)
CRNX : 46.03 (+12.43%)
PFE : 26.59 (+0.11%)
SGEN : 228.74 (-0.07%)
Navigating the Surge in Pancreatic Cancer: The Innovative Strategies Offering New Hope

USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s...

ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
GNLX : 7.27 (-0.41%)
CRNX : 46.03 (+12.43%)
PFE : 26.59 (+0.11%)
SGEN : 228.74 (-0.07%)
Why Shares of Genelux Climbed This Week

The company's shares rose on signs it might be getting closer to its first biologics license application.

GNLX : 7.27 (-0.41%)
Why Shares of Genelux Corporation Jumped This Week

The company reported positive phase 2 trial news regarding its lead therapy.

GNLX : 7.27 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 8.05
2nd Resistance Point 7.85
1st Resistance Point 7.56
Last Price 7.27
1st Support Level 7.07
2nd Support Level 6.87
3rd Support Level 6.58

See More

52-Week High 40.98
Fibonacci 61.8% 27.77
Fibonacci 50% 23.69
Fibonacci 38.2% 19.61
Last Price 7.27
52-Week Low 6.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar